Lessons Learned from COVID-19 Trials – Should We Be Doing Clinical Trials Differently?

Niloufar Yazdanpanah, Constantine Sedikides, Hans D. Ochs, Carlos A. Camargo, Gary L. Darmstadt, Artemi Cerdà, Valentina Cauda, Godefridus J. Peters, Frank W. Sellke, Nathan D. Wong, Elisabetta Comini, A. Ruiz-Jimeno, Vivette Glover, Nikos Hatziargyriou, Christian E. Vincenot, Stéphane Bordas, Idupulapati M. Rao, Hassan Abolhassani, Gevork B. Gharehpetian, Ralf Weiskirchen, Manoj Gupta, Shyam Singh Chandel, Bolajoko O. Olusanya, Bruce D. Cheson,

Lessons Learned from COVID-19 Trials – Should We Be Doing Clinical Trials Differently?

Discussion(0)

Related publications

Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently?

Lessons learned from COVID-19 on potentially pathogenic soil microorganisms

Ten things we learned about COVID-19

Therapeutic strategies for COVID-19: progress and lessons learned

Global Challenges After a Global Challenge: Lessons Learned from the COVID-19 Pandemic